Indonesian President Joko Widodo wearing a protective mask and face shield inspects the third phase trial for COVID-19 vaccine in Bandung, Indonesia, August 11, 2020. China's Sinovac Biotech Ltd launched a late-stage human trial on Tuesday that will involve as many as 1,620 patients in Indonesia for a COVID-19 vaccine candidate that it is developing with Indonesian state-owned peer Bio Farma. Courtesy of Indonesian Presidential Palace/Handout via REUTERS

A healthcare worker checks the tension of a volunteer during a simulation for coronavirus vaccine clinical trials next week at the Faculty of Medicine at Padjadjaran University amid the COVID-19 pandemic in Bandung, Indonesia, August 6, 2020. Separately, Sinovac released details on Monday from a mid-stage, or Phase 2, study in which it said the vaccine candidate appeared to be safe and induced detectable antibody-based immune responses in subjects. REUTERS/Ajeng Dinar Ulfiana

A health worker shows the vaccine during a clinical trial simulation of the COVID-19 vaccine at the Faculty of Medicine, Padjadjaran University, Bandung, West Java. Sinovac's Indonesia trial comes as Southeast Asia's most populous country grapples with spiking infection numbers, with over 127,000 cases recorded as of Tuesday. The trial has so far recruited 1,215 people and will last six months. ANTARA FOTO/M Agung Rajasa

Indonesian President Joko Widodo (2ndR) wearing a protective mask and face shield talks as he inspects the third phase trial for COVID-19 vaccine in Bandung, Indonesia, August 11, 2020. In addition to Bio Farma and Sinovac, private Indonesian firm Kalbe Farma and South Korea's Genexine are cooperating to produce a separate vaccine. It is yet unclear how many doses these partnerships will produce and by when. ANTARA FOTO/HO/dok PT Bio Farma

Indonesian President Joko Widodo wearing a protective mask and face shield inspects the third phase trial for COVID-19 vaccine in Bandung, Indonesia, August 11, 2020. China's Sinovac Biotech Ltd launched a late-stage human trial on Tuesday that will involve as many as 1,620 patients in Indonesia for a COVID-19 vaccine candidate that it is developing with Indonesian state-owned peer Bio Farma. ANTARA FOTO/dok PT Bio Farma

Indonesian President Joko Widodo wearing a protective mask and face shield talks as he inspects the third phase trial for COVID-19 vaccine in Bandung, Indonesia, August 11, 2020. China's Sinovac Biotech Ltd launched a late-stage human trial on Tuesday that will involve as many as 1,620 patients in Indonesia for a COVID-19 vaccine candidate that it is developing with Indonesian state-owned peer Bio Farma. Courtesy of Indonesian Presidential Palace/Handout via REUTERS